Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.50 |
| ▸ | TPSD1 | Q9BZJ3 | 5/20 | 0.50 |
| ▸ | TPSG1 | Q9NRR2 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863355 | 0.93 | TPSAB1 (0.59) | TPSAB1TPSD1TPSG1HTTGNAI3 | |
| SCHEMBL1564353 | 0.85 | KMT2A (0.55) | TPSAB1TPSD1TPSG1HTTGNAI3 | |
| SCHEMBL17934120 | 0.81 | EPHX2 (0.46) | TPSAB1TPSD1TPSG1HTTGNAI3 | |
| SCHEMBL1563438 | 0.81 | KMT2A (0.67) | HTTGNAI3GNAO1GNAI1KMT2A | |
| SCHEMBL15370089 | 0.79 | GNAI3 (0.41) | HTTGNAI3GNAO1GNAI1KMT2A | |
| SCHEMBL13417255 | 0.79 | KMT2A (0.39) | TPSAB1TPSD1TPSG1HTTGNAI3 | |
| SCHEMBL224360 | 0.79 | KMT2A (0.56) | TPSAB1TPSD1TPSG1HTTTDP1 | |
| SCHEMBL771984 | 0.79 | KMT2A (0.56) | TPSAB1TPSD1TPSG1HTTTDP1 | |
| SCHEMBL11745723 | 0.77 | KMT2A (0.58) | TPSAB1TPSD1TPSG1HTTTDP1 | |
| SCHEMBL13972974 | 0.76 | TPSAB1 (0.35) | TPSAB1TPSD1TPSG1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318935-B2 | Organic compounds 75074 | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8318935-B2 | Organic compounds 75074 | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| EP-2332933-A1 | Epithelial sodium channel (ENaC) inhibitors | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2155721-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2155721-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008135557-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | SCNN1A, TRPM4, TRPV4 | TPSAB1 375/4885TPSD1 256/4885TPSG1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.